Pyoderma is one of the the most common diseases not only in dermatological patients (from 17 to 43%), but also in general outpatient population (38%), and in patients on their first visited to surgeon (up 70%). In actual practice, treatment of patients with pyoderma is a challenging issue due to the increased incidence of resistance to therapy. Indications to systemic antibiotic therapy include chronic course, extended process, generalized symptoms, regional complications (lymphadenitis, lymphangitis), localization of deep pyoderma on the face and neck. Minolexin (minocycline) has a broad spectrum of antimicrobial activity, high bacteriostatic activity against sensitive microorganisms, and complies with modern requirements of rational antibiotic therapy. Material and methods. We followed 46 patients aged 18 to 67 years. There was acute inflammatory process in 54.3% of patients; the process lasted more than 2 months in 45.7% of patients (chronic inflammation). The following clinical forms of pyoderma were diagnosed: vulgar impetigo — 13%, boils — 21.7%, periungual phlyctenas — 19.6%, pyoderma of the large folds — 23.9%, erysipelas — 21.7%. Results. Comprehensive treatment of acute pyoderma led to clinical improvement in 22 (88%) patients. In 2 (8%) patients with pyoderma of the large folds and 1 (4%) patient with erysipelas, the effect was rated as inadequate on day 3 of treatment, and therefore the treatment strategy was changed. In patients with chronic forms of pyoderma, efficacy was 18 (85.7%), 3 (14.3%) patients with erysipelas had disease recurrence in the late follow-up (2 months). Conclusion. Minolexin demonstrated high efficacy against various clinical forms of pyoderma and can be recommended for effective use in clinical practice.